- From Iron Hands to Printed Organs
About the Panelists Maryaline Catillon is a Ph.D. candidate in Health Policy and Management at Harvard University and a pre-doctoral fellow in the NBER-IFS International Network on the Value of Medical Research. Her research focuses on issues at the intersection of health policy and innovation policy. Prior to Harvard, Maryaline worked as a Hospital Director in France. She holds a B.S. in Mathematics and Physics (Paris) and an MPH from the Pasteur Institute - CNAM School of Public Health (Paris). Maryaline is also a Vice-President and Board Member of the Sergei S Zlinkoff Fund for Medical Research and Education, as well as a member of the American Society of Health Economists, Association des Directeurs d'Hôpital, and former Chair of the French–American Conference on Hospital Innovation.
Dr. Jean-Luc Boulnois, Ph.D., is Chief Executive Officer of Quadrature LLC, a strategic advisory firm for device companies, and partner of several venture capital-backed medical device companies. He has over 30 years of international leadership experience in creating, operating, and financing medical device companies. For 11 years Dr. Boulnois was Chairman and CEO, and subsequently Executive Chairman, of Microline Surgical, a worldwide leader in electro-surgical instruments. He was also Executive Director at Arrow International; co-developer, President, and CEO of Sometec, an innovative company in non-invasive cardiovascular monitoring; and served as Director of Mauna Kea Technologies (Euronext: MKEA) Dr. Boulnois is co-author of 6 books and more than 35 peer-reviewed scientific articles in applied physics and biophysics. He is an Adjunct Professor of Entrepreneurship at Babson College, and was previously a lecturer at Princeton University and visiting professor at HEC in Paris. He holds an MSc. from Paris University, an EMBA from HEC, and a Ph.D. from Princeton University.
Dr. Edward Kaye, M.D. is the Chief Executive Officer and a Director of Stoke Therapeutics and member of the Boards of Directors of Cytokinetics, Inc. and The Massachusetts Biotechnology Council. Previously, Dr. Kaye served as the Chief Executive Officer, Chief Medical Officer, and former Director of Sarepta Therapeutics. Prior to joining Sarepta, Dr. Kaye held various senior management positions at Genzyme Corporation, including Group Vice President of Clinical Development, Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Prior to entering the biotech industry, Dr. Kaye trained in Pediatrics, Pediatric Neurology, and Biochemical Genetics. He was on the research staff of the Massachusetts General Hospital, Tufts University Medical Center, and was the Chief of Biochemical Genetics at the Children’s Hospital of Philadelphia. He continues on staff in Pediatric Neurology at the Boston Children’s Hospital. Ed earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine.